Results 91 to 100 of about 21,353 (254)

Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity. [PDF]

, 2013
A crisis continues to brew within the pharmaceutical research and development (R&D) enterprise: productivity continues declining as costs rise, despite ongoing, often dramatic scientific and technical advances. To reverse this trend, we offer various
Hunt, C. Anthony, Hunt, CA, Kennedy, RC, Kim, SHJ, Ropella, GEP   +4 more
core   +2 more sources

Recent advances: rheumatology [PDF]

, 2000
No abstract ...
Madhok, R., Kerr, H., Capell, H.A.
core   +4 more sources

Characteristics of Patients with Hereditary Transthyretin Amyloidosis and an Evaluation of the Safety of Tafamidis Meglumine in Japan: An Interim Analysis of an All-case Postmarketing Surveillance [PDF]

, 2020
Tomonori Ishii, Yoko Hirano, Noriko Matsumoto, Ami Takata, Yoshiki Sekijima, Mitsuharu Ueda, Yukio Ando   +6 more
openalex   +1 more source

Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan [PDF]

, 2022
Masataka Kuwana, Naoko Wakasugi, Toshinori Furuya, Satoshi Uno, Takafumi Suda   +4 more
openalex   +1 more source

MDDC: An R and Python package for adverse event identification in pharmacovigilance data

Scientific Reports
The safety of medical products continues to be a significant health concern worldwide. Spontaneous reporting systems (SRS) and pharmacovigilance databases are essential tools for postmarketing surveillance of medical products.
Anran Liu, Raktim Mukhopadhyay, Marianthi Markatou   +2 more
doaj   +1 more source

Incidence of Uveitis in Secukinumab‐treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies

ACR Open Rheumatology, 2020
Objective The objective of this study was to report the incidence of uveitis in secukinumab‐treated patients with ankylosing spondylitis (AS) in a pooled analysis of three phase 3 trials (MEASURE 1‐3 [ClinicalTrials.gov identifiers NCT01358175 ...
Atul A. Deodhar, Corine Miceli‐Richard, Xenofon Baraliakos, Helena Marzo‐Ortega, Dafna D. Gladman, Ricardo Blanco, Ayan Das Gupta, Ruvie Martin, Jorge Safi Jr, Brian Porter, Abhijit Shete, James T. Rosenbaum   +11 more
doaj   +1 more source

SAFETY EVALUATION OF STATIN IN YOGYAKARTA, INDONESIA [PDF]

, 2009
Background : The 3-hydroxy-3-methylglutaryl-coenzyme (HMG-Co-A) reductase inhibitors, also known as statins, are the most effective class of drugs for lowering serum Low-Density Lipoprotein cholesterol (LDL-c)concentrations.
Anni, Anni, Labado, R.O., Perwitasari, Dyah Aryani, Udu, W.S.A.   +3 more
core  

The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements [PDF]

, 2018
The United States Food and Drug Administration (FDA) has several regulatory programs and pathways to expedite the development and approval of therapeutic agents aimed at treating serious or life-debilitating conditions. A common feature of these programs
Naci, Huseyin, Ross, Joseph S., Wallach, Joshua D.   +2 more
core   +1 more source

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system

, 2023
Yamin Shu, Jing Chen, Yiling Ding, Qilin Zhang   +3 more
openalex   +1 more source

Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

Neuropsychiatric Disease and Treatment, 2013
Michele Jara,1 Graham Barker,2 Herbert R Henney 3rd1 1Acorda Therapeutics, Inc, Ardsley, NY, USA; 2Biogen Idec, Inc, Maidenhead, Berkshire, UK Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained ...
Jara M, Barker G, Henney 3rd HR
doaj